mefloquine hydrochloride has been researched along with Infections, Plasmodium in 27 studies
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study represents the first phase III trial of the safety, tolerability, and effectiveness of tafenoquine for malaria prophylaxis." | 9.14 | Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. ( Brennan, L; Edstein, MD; Harris, IE; Kerr, C; Kitchener, SJ; Leggat, PA; Nasveld, PE; Ohrt, C; Pickford, P; Prescott, W; Reid, M, 2010) |
| "Sixteen new artemisinin-derived 2-carbon-linked trioxane dimers were prepared to study chemical structure/antimalarial activity relationships (SAR)." | 7.80 | The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether. ( Conyers, RC; Mazzone, JR; Mott, BT; Posner, GH; Siegler, MA; Sullivan, DJ; Tripathi, AK, 2014) |
| "Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P." | 7.77 | In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. ( Anstey, NM; Chalfein, F; Ebsworth, EP; Kenangalem, E; Marfurt, J; Piera, KA; Prasetyorini, B; Price, RN; Ratcliff, A; Russell, B; Siswantoro, H; Tjitra, E; Wuwung, M, 2011) |
| "In an attempt to augment the efficacy of 7-chloro 4-aminoquinoline analogs and also to overcome resistance to antimalarial agents, we synthesized three cyclen (1,4,7,10-tetraazacyclododecane) analogs of chloroquine [a bisquinoline derivative, 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline HBr, and a 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline-Zn(2+) complex]." | 7.75 | Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs. ( Borne, RF; Khan, MO; Khan, SI; Kimura, E; Levi, MS; Tekwani, BL, 2009) |
| "The synthesis of deoxycholic acid (DCA)- and cholic acid (CA)-derived mixed tetraoxanes revealed that N-(2-dimethylamino)ethyl derivatives are potent antimalarials in vitro and in vivo." | 7.74 | Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1). ( Milhous, WK; Milić, D; Opsenica, D; Smith, KS; Solaja, BA; Terzić, N; Tinant, B, 2007) |
| "Using easily accessible keto-trioxanes 7a-g as the starting materials, a series of new variously functionalized 1,2,4-trioxanes 10-36 have been prepared and evaluated for antimalarial activity against multi-drug-resistant Plasmodium yoelii nigeriensis in mice in the dose range of 24 mg/kg x 4 days to 96 mg/kg x 4 days by oral route." | 7.73 | Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice. ( Malik, H; Puri, SK; Singh, C, 2006) |
| "Febrifugine is an alkaloid isolated from Dichroa febrifuga Lour as the active component against Plasmodium falciparum, but exhibits toxic side effects." | 5.38 | Febrifugine analogue compounds: synthesis and antimalarial evaluation. ( Chandrashekar, G; Chatterji, D; Meng, L; Robinson, K; Zhu, S, 2012) |
| "This study represents the first phase III trial of the safety, tolerability, and effectiveness of tafenoquine for malaria prophylaxis." | 5.14 | Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. ( Brennan, L; Edstein, MD; Harris, IE; Kerr, C; Kitchener, SJ; Leggat, PA; Nasveld, PE; Ohrt, C; Pickford, P; Prescott, W; Reid, M, 2010) |
| "Chloroquine (CQ) has been used as first line malaria therapeutic drug for decades." | 3.81 | Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives. ( Caridha, D; Gerena, L; Korotchenko, V; Kreishman-Deitrick, M; Li, Q; Lin, AJ; Sathunuru, R; Smith, PL, 2015) |
| "Sixteen new artemisinin-derived 2-carbon-linked trioxane dimers were prepared to study chemical structure/antimalarial activity relationships (SAR)." | 3.80 | The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether. ( Conyers, RC; Mazzone, JR; Mott, BT; Posner, GH; Siegler, MA; Sullivan, DJ; Tripathi, AK, 2014) |
| "Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P." | 3.77 | In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. ( Anstey, NM; Chalfein, F; Ebsworth, EP; Kenangalem, E; Marfurt, J; Piera, KA; Prasetyorini, B; Price, RN; Ratcliff, A; Russell, B; Siswantoro, H; Tjitra, E; Wuwung, M, 2011) |
| "Drug resistance against dihydrofolate reductase (DHFR) inhibitors-such as pyrimethamine (PM)-has now spread to almost all regions where malaria is endemic, rendering antifolate-based malaria treatments highly ineffective." | 3.76 | Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate. ( Brun, R; Chitnumsub, P; Dartois, V; Diagana, TT; Goh, A; Kamchonwongpaisan, S; Keller, TH; Kiara, SM; Lakshminarayana, SB; Ma, NL; Maneeruttanarungroj, C; Nzila, A; Rottmann, M; Taweechai, S; Weaver, M; Wittlin, S; Wong, J; Yeung, BK; Yuthavong, Y; Zou, B, 2010) |
| "In an attempt to augment the efficacy of 7-chloro 4-aminoquinoline analogs and also to overcome resistance to antimalarial agents, we synthesized three cyclen (1,4,7,10-tetraazacyclododecane) analogs of chloroquine [a bisquinoline derivative, 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline HBr, and a 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline-Zn(2+) complex]." | 3.75 | Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs. ( Borne, RF; Khan, MO; Khan, SI; Kimura, E; Levi, MS; Tekwani, BL, 2009) |
| "The synthesis of deoxycholic acid (DCA)- and cholic acid (CA)-derived mixed tetraoxanes revealed that N-(2-dimethylamino)ethyl derivatives are potent antimalarials in vitro and in vivo." | 3.74 | Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1). ( Milhous, WK; Milić, D; Opsenica, D; Smith, KS; Solaja, BA; Terzić, N; Tinant, B, 2007) |
| " Their antimalarial effects have been characterized in parasite assays using chloroquine-sensitive and -resistant strains of Plasmodium, alone or in drug combination, and in the Plasmodium berghei rodent model." | 3.74 | Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum. ( Becker, K; Davioud-Charvet, E; Friebolin, W; Furrer, J; Jannack, B; Lanzer, M; Oeser, T; Sanchez, CP; Wenzel, N; Yardley, V, 2008) |
| "Using easily accessible keto-trioxanes 7a-g as the starting materials, a series of new variously functionalized 1,2,4-trioxanes 10-36 have been prepared and evaluated for antimalarial activity against multi-drug-resistant Plasmodium yoelii nigeriensis in mice in the dose range of 24 mg/kg x 4 days to 96 mg/kg x 4 days by oral route." | 3.73 | Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice. ( Malik, H; Puri, SK; Singh, C, 2006) |
| "Febrifugine is an alkaloid isolated from Dichroa febrifuga Lour as the active component against Plasmodium falciparum, but exhibits toxic side effects." | 1.38 | Febrifugine analogue compounds: synthesis and antimalarial evaluation. ( Chandrashekar, G; Chatterji, D; Meng, L; Robinson, K; Zhu, S, 2012) |
| "Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance." | 1.37 | Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. ( Bathurst, I; Buckner, FS; Burrows, J; Charman, SA; Charman, WN; Creason, S; Deng, X; El Mazouni, F; Floyd, DM; Gujjar, R; Matthews, D; Phillips, MA; Rathod, PK; Shackleford, DM; White, J; White, KL, 2011) |
| " The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity." | 1.37 | Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. ( Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011) |
| " The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model." | 1.36 | Spiroindolones, a potent compound class for the treatment of malaria. ( Beck, HP; Brun, R; Cohen, SB; Dartois, V; Dharia, NV; Diagana, TT; Fidock, DA; Goh, A; González-Páez, GE; Jegla, T; Keller, TH; Lakshminarayana, SB; Lee, MC; McNamara, C; Nosten, F; Plouffe, DM; Renia, L; Rottmann, M; Russell, B; Schmitt, EK; Seitz, P; Spencer, KR; Suwanarusk, R; Tan, J; Winzeler, EA; Yeung, BK; Zou, B, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 14 (51.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brossi, A | 1 |
| Venugopalan, B | 1 |
| Dominguez Gerpe, L | 1 |
| Yeh, HJ | 1 |
| Flippen-Anderson, JL | 1 |
| Buchs, P | 1 |
| Luo, XD | 1 |
| Milhous, W | 2 |
| Peters, W | 2 |
| Avery, MA | 1 |
| Alvim-Gaston, M | 1 |
| Vroman, JA | 1 |
| Wu, B | 1 |
| Ager, A | 2 |
| Robinson, BL | 1 |
| Charman, W | 1 |
| Nallan, L | 1 |
| Bauer, KD | 1 |
| Bendale, P | 1 |
| Rivas, K | 1 |
| Yokoyama, K | 1 |
| Hornéy, CP | 1 |
| Pendyala, PR | 1 |
| Floyd, D | 1 |
| Lombardo, LJ | 1 |
| Williams, DK | 1 |
| Hamilton, A | 1 |
| Sebti, S | 1 |
| Windsor, WT | 1 |
| Weber, PC | 1 |
| Buckner, FS | 2 |
| Chakrabarti, D | 1 |
| Gelb, MH | 1 |
| Van Voorhis, WC | 1 |
| Zhang, Q | 1 |
| Guan, J | 1 |
| Sacci, J | 1 |
| Ellis, W | 1 |
| Kyle, D | 1 |
| Lin, AJ | 2 |
| Singh, C | 1 |
| Malik, H | 1 |
| Puri, SK | 1 |
| Terzić, N | 1 |
| Opsenica, D | 3 |
| Milić, D | 1 |
| Tinant, B | 1 |
| Smith, KS | 2 |
| Milhous, WK | 2 |
| Solaja, BA | 3 |
| Friebolin, W | 1 |
| Jannack, B | 1 |
| Wenzel, N | 1 |
| Furrer, J | 1 |
| Oeser, T | 1 |
| Sanchez, CP | 1 |
| Lanzer, M | 1 |
| Yardley, V | 1 |
| Becker, K | 1 |
| Davioud-Charvet, E | 1 |
| Plouffe, D | 2 |
| Brinker, A | 1 |
| McNamara, C | 2 |
| Henson, K | 1 |
| Kato, N | 2 |
| Kuhen, K | 2 |
| Nagle, A | 3 |
| Adrián, F | 1 |
| Matzen, JT | 1 |
| Anderson, P | 1 |
| Nam, TG | 2 |
| Gray, NS | 1 |
| Chatterjee, A | 2 |
| Janes, J | 1 |
| Yan, SF | 1 |
| Trager, R | 1 |
| Caldwell, JS | 1 |
| Schultz, PG | 2 |
| Zhou, Y | 2 |
| Winzeler, EA | 3 |
| Dow, GS | 1 |
| Chen, Y | 1 |
| Andrews, KT | 1 |
| Caridha, D | 3 |
| Gerena, L | 3 |
| Gettayacamin, M | 4 |
| Johnson, J | 2 |
| Li, Q | 3 |
| Melendez, V | 2 |
| Obaldia, N | 1 |
| Tran, TN | 1 |
| Kozikowski, AP | 1 |
| Opsenica, I | 2 |
| Lanteri, CA | 2 |
| Anova, L | 1 |
| Khan, MO | 1 |
| Levi, MS | 1 |
| Tekwani, BL | 1 |
| Khan, SI | 1 |
| Kimura, E | 1 |
| Borne, RF | 1 |
| O'Neill, PM | 2 |
| Park, BK | 2 |
| Shone, AE | 2 |
| Maggs, JL | 2 |
| Roberts, P | 2 |
| Stocks, PA | 2 |
| Biagini, GA | 1 |
| Bray, PG | 2 |
| Gibbons, P | 1 |
| Berry, N | 2 |
| Winstanley, PA | 2 |
| Mukhtar, A | 1 |
| Bonar-Law, R | 1 |
| Hindley, S | 2 |
| Bambal, RB | 2 |
| Davis, CB | 2 |
| Bates, M | 2 |
| Hart, TK | 1 |
| Gresham, SL | 2 |
| Lawrence, RM | 1 |
| Brigandi, RA | 2 |
| Gomez-delas-Heras, FM | 1 |
| Gargallo, DV | 2 |
| Ward, SA | 2 |
| Stanford, D | 1 |
| Nixon, G | 1 |
| Asadollahy, E | 1 |
| Biagini, G | 1 |
| Davies, J | 1 |
| Hall, C | 1 |
| Rimmer, K | 1 |
| Gomez-de-Las-Heras, FM | 1 |
| Parapini, S | 1 |
| Vivas, L | 1 |
| Lander, H | 1 |
| Taramelli, D | 2 |
| Nasveld, PE | 1 |
| Edstein, MD | 1 |
| Reid, M | 1 |
| Brennan, L | 1 |
| Harris, IE | 1 |
| Kitchener, SJ | 1 |
| Leggat, PA | 1 |
| Pickford, P | 1 |
| Kerr, C | 1 |
| Ohrt, C | 1 |
| Prescott, W | 1 |
| Nzila, A | 1 |
| Rottmann, M | 4 |
| Chitnumsub, P | 1 |
| Kiara, SM | 1 |
| Kamchonwongpaisan, S | 1 |
| Maneeruttanarungroj, C | 1 |
| Taweechai, S | 1 |
| Yeung, BK | 2 |
| Goh, A | 3 |
| Lakshminarayana, SB | 3 |
| Zou, B | 2 |
| Wong, J | 1 |
| Ma, NL | 1 |
| Weaver, M | 1 |
| Keller, TH | 2 |
| Dartois, V | 3 |
| Wittlin, S | 1 |
| Brun, R | 3 |
| Yuthavong, Y | 1 |
| Diagana, TT | 3 |
| Lee, MC | 2 |
| Russell, B | 2 |
| Seitz, P | 1 |
| Plouffe, DM | 2 |
| Dharia, NV | 2 |
| Tan, J | 1 |
| Cohen, SB | 1 |
| Spencer, KR | 1 |
| González-Páez, GE | 1 |
| Suwanarusk, R | 1 |
| Jegla, T | 1 |
| Schmitt, EK | 1 |
| Beck, HP | 1 |
| Nosten, F | 1 |
| Renia, L | 1 |
| Fidock, DA | 2 |
| Siswantoro, H | 1 |
| Ratcliff, A | 1 |
| Prasetyorini, B | 1 |
| Chalfein, F | 1 |
| Marfurt, J | 1 |
| Kenangalem, E | 1 |
| Wuwung, M | 1 |
| Piera, KA | 1 |
| Ebsworth, EP | 1 |
| Anstey, NM | 1 |
| Tjitra, E | 1 |
| Price, RN | 1 |
| Burnett, JC | 1 |
| Gussio, R | 1 |
| Todorović, N | 1 |
| Sciotti, RJ | 1 |
| Basilico, N | 1 |
| Nuss, JE | 1 |
| Wanner, L | 1 |
| Panchal, RG | 1 |
| Bavari, S | 1 |
| Gujjar, R | 1 |
| El Mazouni, F | 1 |
| White, KL | 2 |
| White, J | 1 |
| Creason, S | 1 |
| Shackleford, DM | 2 |
| Deng, X | 1 |
| Charman, WN | 1 |
| Bathurst, I | 2 |
| Burrows, J | 1 |
| Floyd, DM | 1 |
| Matthews, D | 1 |
| Charman, SA | 2 |
| Phillips, MA | 1 |
| Rathod, PK | 1 |
| Ndakala, AJ | 1 |
| Gessner, RK | 1 |
| Gitari, PW | 1 |
| October, N | 1 |
| Hudson, A | 1 |
| Fakorede, F | 1 |
| Kaiser, M | 1 |
| Yeates, C | 1 |
| Chibale, K | 1 |
| Wu, T | 2 |
| Gagaring, K | 2 |
| Borboa, R | 2 |
| Francek, C | 1 |
| Chen, Z | 1 |
| Wu, J | 1 |
| Ang, HQ | 1 |
| Zeng, P | 1 |
| Kang, ML | 1 |
| Tan, W | 1 |
| Tan, M | 1 |
| Ye, N | 1 |
| Lin, X | 1 |
| Caldwell, C | 1 |
| Ek, J | 1 |
| Skolnik, S | 1 |
| Liu, F | 1 |
| Wang, J | 1 |
| Chang, J | 1 |
| Li, C | 1 |
| Hollenbeck, T | 1 |
| Tuntland, T | 2 |
| Isbell, J | 1 |
| Fischli, C | 1 |
| Keller, T | 1 |
| Diagana, T | 1 |
| Winzeler, E | 1 |
| Glynne, R | 1 |
| Tully, DC | 1 |
| Chatterjee, AK | 1 |
| Milner, E | 1 |
| Gardner, S | 1 |
| Moon, J | 1 |
| Grauer, K | 1 |
| Auschwitz, J | 1 |
| Kozar, M | 1 |
| Lee, P | 1 |
| Leed, S | 1 |
| McCalmont, W | 1 |
| Roncal, N | 1 |
| Sciotti, R | 1 |
| Smith, B | 1 |
| Sousa, J | 1 |
| Tungtaeng, A | 1 |
| Wipf, P | 1 |
| Dow, G | 1 |
| Sá, MS | 1 |
| de Menezes, MN | 1 |
| Krettli, AU | 1 |
| Ribeiro, IM | 1 |
| Tomassini, TC | 1 |
| Ribeiro dos Santos, R | 1 |
| de Azevedo, WF | 1 |
| Soares, MB | 1 |
| Meister, S | 1 |
| Kuhen, KL | 1 |
| Bonamy, GM | 1 |
| Barnes, SW | 1 |
| Bopp, SE | 1 |
| Bright, AT | 1 |
| Che, J | 1 |
| Cohen, S | 1 |
| Gordon, P | 1 |
| Groessl, T | 1 |
| McNamara, CW | 1 |
| Richmond, W | 1 |
| Roland, J | 1 |
| Zhou, B | 1 |
| Froissard, P | 1 |
| Glynne, RJ | 1 |
| Mazier, D | 1 |
| Sattabongkot, J | 1 |
| Walker, JR | 1 |
| Zhu, S | 1 |
| Chandrashekar, G | 1 |
| Meng, L | 1 |
| Robinson, K | 1 |
| Chatterji, D | 1 |
| Conyers, RC | 1 |
| Mazzone, JR | 1 |
| Siegler, MA | 1 |
| Tripathi, AK | 1 |
| Sullivan, DJ | 1 |
| Mott, BT | 1 |
| Posner, GH | 1 |
| Korotchenko, V | 1 |
| Sathunuru, R | 1 |
| Kreishman-Deitrick, M | 1 |
| Smith, PL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-10 | Not yet recruiting | ||
| Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?[NCT05788094] | Phase 4 | 388 participants (Anticipated) | Interventional | 2023-06-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mefloquine hydrochloride and Infections, Plasmodium
| Article | Year |
|---|---|
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male | 2010 |
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male | 2010 |
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male | 2010 |
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male | 2010 |
26 other studies available for mefloquine hydrochloride and Infections, Plasmodium
| Article | Year |
|---|---|
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
Topics: Animals; Antimalarials; Artemisinins; Magnetic Resonance Spectroscopy; Malaria; Mice; Models, Molecu | 1988 |
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
Topics: Administration, Oral; Animals; Antimalarials; Artemisinins; Drug Evaluation, Preclinical; Drug Resis | 2002 |
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
Topics: Alkyl and Aryl Transferases; Animals; Antimalarials; Cells, Cultured; Electrophoresis, Polyacrylamid | 2005 |
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
Topics: Administration, Oral; Animals; Antimalarials; Carbamates; Guanidines; Imidazoles; Imidazolidines; Ma | 2005 |
Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.
Topics: Administration, Oral; Amination; Animals; Antimalarials; Artemisinins; Drug Resistance, Multiple; He | 2006 |
Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1).
Topics: Animals; Antimalarials; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Cyclohexane | 2007 |
Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum.
Topics: Animals; Antimalarials; Biological Transport; Cell Line, Tumor; Chloroquine; Drug Resistance; Drug T | 2008 |
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
Topics: Animals; Antimalarials; Cluster Analysis; Computational Biology; Drug Evaluation, Preclinical; Drug | 2008 |
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
Topics: Animals; Antimalarials; Aotidae; Drug Resistance; Enzyme Inhibitors; Histone Deacetylase Inhibitors; | 2008 |
New chimeric antimalarials with 4-aminoquinoline moiety linked to a tetraoxane skeleton.
Topics: Aminoquinolines; Animals; Antimalarials; Binding Sites; Disease Models, Animal; Dose-Response Relati | 2008 |
Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Cyclams; Hemeproteins; Heterocyclic Compounds; | 2009 |
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Benzylamines; Cytochrome P-450 Enzyme Inhibito | 2009 |
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Cell Survival; Chloroquine; Dogs; Drug Resista | 2009 |
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
Topics: Administration, Oral; Animals; Antimalarials; Biological Availability; Drug Resistance; Female; Foli | 2010 |
Spiroindolones, a potent compound class for the treatment of malaria.
Topics: Adenosine Triphosphatases; Animals; Antimalarials; Cell Line; Drug Discovery; Drug Resistance; Eryth | 2010 |
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Female; Humans; Indonesia; M | 2011 |
A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.
Topics: Animals; Anopheles; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Botulinum Toxins, Type A | 2011 |
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
Topics: Animals; Antimalarials; Dihydroorotate Dehydrogenase; Disease Models, Animal; Drug Design; Drug Disc | 2011 |
Antimalarial pyrido[1,2-a]benzimidazoles.
Topics: Administration, Oral; Animals; Antimalarials; Benzimidazoles; Drug Resistance, Multiple; Humans; In | 2011 |
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
Topics: Amino Acids; Aniline Compounds; Animals; Antimalarials; Benzene Derivatives; Cell Line; Drug Resista | 2011 |
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
Topics: Animals; Antimalarials; Cell Line; Cell Membrane Permeability; Dimerization; Dogs; Drug Resistance; | 2011 |
Antimalarial activity of physalins B, D, F, and G.
Topics: Animals; Antimalarials; Immunosuppressive Agents; Malaria; Mice; Mice, Inbred BALB C; Parasitemia; P | 2011 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resista | 2011 |
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
Topics: Animals; Antimalarials; Aotus trivirgatus; Drug Evaluation, Preclinical; Malaria; Piperidines; Plasm | 2012 |
The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether.
Topics: Animals; Antimalarials; Artemether; Artemisinins; Carbamates; Carbon; Crystallography, X-Ray; Dimeri | 2014 |
Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives.
Topics: Animals; Antimalarials; Hep G2 Cells; Humans; Malaria; Malaria, Falciparum; Male; Mice; Naphthyridin | 2015 |